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We compared fecal microbial communities derived either from Ulcerative Colitis (UC) patients in
remission (n54) or in relapse (n54), or from healthy subjects (n54). These communities were used for
inoculation of a dynamic in vitro gut model, which contained integrated mucin-covered microcosms. We
found that the microbiota of the ‘mucus’ largely differed from that of the ‘lumen’. This was partly due to
decreased mucus-associated populations of lactic acid producing bacterial populations (LAB), as LAB
originating from UC patients had a significantly decreased capacity to colonize the mucin-covered
microcosms as compared to those originating from healthy subjects. We found significant differences
between the metabolomes of UC patients in relapse and remission, respectively, while the metabolome of
patients in remission resembled that of healthy subjects. These novel findings constitute an important
contribution to the understanding of the complex etiology of UC.
T
he mucus layer lining the epithelium of the gastrointestinal tract is important for the protection of the
intestinal epithelium in humans. Commensal bacteria have been found to colonize the colonic mucus layer,
and previous studies have shown that themicrobial community found in the colonicmucus differs from that
of the luminal community1,2. Several microbial characteristics have contributed to the evolvement of the specif-
ically selected mucosal community, including the ability of the bacteria to utilize mucin glycans as energy source
as well as resistance to nonspecific antimicrobial peptides and specific antimicrobial immunoglobulins produced
by the host3,4. Additionally, many adhesion molecules expressed by colonic bacteria have mucin glycans as
specific epitopes5,6, and it has been suggested that the glycosylation pattern in mucin, hence the attachment site
and energy source for the colonic bacteria, is an important factor for host selection of a specific mucosal
community3. Lack or defects in themucosal barrier may allow bacteria to reach the epithelium and trigger colonic
inflammation.
Ulcerative colitis (UC) is an idiopathic inflammatory bowel disease characterized by chronic relapsing inflam-
mation of the colonic mucosa7. The etiology of UC remains an enigma, and no known infectious agent has been
demonstrated8,9. It has been speculated that UC originates from a dysregulated immune response to the com-
mensal intestinal microbiota in genetically susceptible individuals10,11. Human studies have revealed that UC
patients have a colonic mucus layer that has an altered O-glycan profile and is significantly thinner than that of
healthy subjects, which may select for a different mucosal microbial profile12,13. Consistently, several studies have
shown that patients with UC have an altered bacterial microbiota14–18. Thus, the bacterial and/or host-bacterial
interactions may play a role in the pathogenesis of UC.
In vitro models are well-suited to screen the adhering potency of intestinal microbes. They include adhesion
assays to various components of the intestinal surface: e.g. intestinal mucus19, mucins20, colonic tissue21 or cell
lines22. A drawback to such models is that they often provide only short-term information based on axenic
cultures and thus ignore the interactions between and within the luminal and mucosal microbial communities.
Therefore, a dynamic in vitro gut model has been developed, which simulates both the luminal and mucosal
environment23. This model, named the M-SHIME was adapted from the validated Simulator of the Human
Intestinal Microbial Ecosystem (SHIME)24. Compared to earlier in vitro models, the M-SHIME allows a more
representative colonization of specific Lactobacillus sp23. Furthermore, high-resolution phylogenetic microbiota
profiling shows that the simulated mucosal microbiota is, in correspondence with in vivo studies, enriched with
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Firmicutes belonging to the Clostridial clusters IV and XIVa24.
Moreover, the in vitro mucosal environment is necessary to avoid
the wash-out of specific surface-associatedmicrobes, which occurs in
conventional in vitromodels. Hence, theM-SHIME allows studies of
the mucosal microbiota and the interaction between luminal and
mucosal microbial communities.
The aims of this study were (1) to investigate the ability of fecal
microbiota fromhealthy subjects andUCpatients in either remission
or relapse to colonize the artificial mucus layer of the M-SHIME and
(2) to elucidate microbial activity by comparison of metabolic pro-
files of the luminal and mucosal microbial communities derived
from UC patients and healthy subjects. Denaturing Gradient Gel
Electrophoresis (DGGE) and quantitative Real-Time PCR (qPCR),
both of which are culture-independent methods, were applied for
microbiota analysis, while Liquid Chromatography – Mass Spectro-
scopy (LC-MS) was used to analyze the potential role of extracellular
metabolites produced bymicroorganisms in the lumen andmucus of
the M-SHIME.
Results
Microbial activity in terms of SCFA production. SCFA were
analyzed in the luminal content of the colonic M-SHIME vessels as
a measure of the metabolic activity of the microbiota derived from
healthy subjects or UC patients, either in remission or relapse
(Table 1). Forty-two hours after inoculation with fecal samples,
there was a significant inter-individual variability within each
group regarding the conversion of the provided nutrients to SCFA
(P,0.05). As a result of this variability, no significant differences
were detectable between the three groups. However, there was a
trend of lower acetate and higher branched SCFA concentrations
for UC patients as opposed to healthy subjects (P50.138 and
P50.210, respectively). Additionally, we found it noteworthy that
the levels of carproate found in samples containing microbiota from
patients in remission was 36 fold higher than in samples with
microbiota from patients in relapse (P50.229).
Microbial community analysis using DGGE. Comparison of
DGGE profiles containing 16S ribosomal genes amplified from
luminal and mucosal samples of healthy subjects and UC patients
after 42 h colonization revealed a distinct difference between the
dominant bacterial members of the luminal and mucosal environ-
ment (Figure 1). The dendrogram from the Dice cluster analysis
showed three clusters with all mucosal samples in cluster I (54.61%
similarity), five luminal samples in cluster II (53.89% similarity), and
seven luminal samples in cluster III (41.15% similarity). Clustering of
the distribution of these dominantmicrobial species did not correlate
to the health status of the human subjects (healthy, UC in remission
and UC in relapse).
Microbial community analysis by qPCR. For microbiotas derived
from UC patients in relapse or remission, luminal and mucosal
samples were separated from one another, while this separation
was not equally clear for samples from healthy subjects (Figure 2,
score plot). Roseburia, Faecalibacterium prautznitzii, and Closteri-
diaceae/Eubacterium represented samples from the mucosal envi-
ronment, while and B. bifidum, B. adolescentis, Bifidobacterium
spp., Lactobacillus spp., Akk. muciniphila and Actinobacteria repre-
sented the luminal content samples (Figure 2, loading plot).
It was noteworthy that the preference of specific bacterial groups
to colonize the mucosal and/or luminal compartment was clearly
affected by the origin of themicrobiota (healthy subjects, UCpatients
in remission or UC patients in relapse) (Table 2). No significant
differences between the luminal and mucosal samples with respect
to proportions of specific bacterial taxa were measured when fecal
communities were derived from healthy subjects. However, in the
vessels with communities derived from UC patients in relapse,
mucus was colonized by significantly lower proportions of bifido-
bacteria, B. bifidum, lactobacilli, C. coccoides group, C. leptum sub-
group and Alistipes spp.(P50.01, P50.02, P50.03, P50.05, P50.02,
and P50.05, respectively) than found in lumen. Additionally, the
densities of bifidobacteria, B. adolescentis, B. pseudocatenulatum,
lactobacilli, C. leptum subgroup, Faecalibacterium prausnitzii and
Actinobacteria derived from UC patients in remission were signifi-
cantly lower in mucus than in lumen (P50.01, P50.001, P50.01,
P50.007 and P50.05, P50.03 and P50.001, respectively). Finally,
significantly higher mucosal counts of Roseburia spp. derived from
UC patients in remission were measured (P50.05).
Comparison of the proportions of specific taxa present in the
luminal and mucosal compartments, respectively, from the three
types of microbiota (healthy, UC remission, UC relapse) revealed
that relative quantities of Bifidobacterium spp. and Lactobacillus
spp. inmucus was significantly lower (P50.05 and P50.002, respect-
ively) in communities derived from UC patients in relapse than in
those derived from healthy subjects, whereas the relative quantity of
Clostridiaceae/Eubacterium was significantly higher in the lumen
(P50.04) in communities from UC patients in relapse than in those
from healthy subjects (Table 3).
The bacterial growth rate of selected bacterial taxa in the lumen
was calculated from the slope of the exponential phase of the growth
curves. The growth rate was increased during the 42 h incubation in
the lumen for all the examined bacterial taxa. No significant differ-
ence in the growth rate for each bacterial taxon was found when
comparing the three groups (healthy subjects, UC in remission or
UC in relapse) (Table S3, supplementary data).
Metabolite detection and separation. PCA of the metabolites as
detected by LCMS revealed a difference between samples taken
from healthy subjects and UC patients in relapse, respectively. The
grouping was present in samples frommucus (Figure 3, score plot) as
well as from lumen (Figure 4, score plot). No difference was observed
between UC patients in remission and healthy subjects (Figure S1
and S2, supplementary data). However, a clear separation between
score plots forUC patients in relapse and remission, respectively, was
seen (Figure S3 and S4, supplementary data).
Based on the PCA loading plots (Figure 3 and 4), metabolites,
which were tentatively causative for the difference observed between
UC patients in relapse and healthy subjects, were identified (Table 4
and 5). Loadings, which in extracted ion chromatograms showed
clear chromatogram peaks (data not shown) that were present in
significantly different levels (P,0.05) in the two groups were further
investigated. Substances in theHumanMetabolomeDatabase, which
corresponded to the found mass/charge ratio (MLCMS) were iden-
tified. However, a few of the givenmass/charge values hadmore than
one possible match (Table 4 and 5).
Discussion
In this study, we applied a recently developed dynamic in vitro
gut model, the M-SHIME, to investigate differences between the
Table 1 | The average (6 SEM) absolute SCFA levels (mM) in the
luminal content of the M-SHIME units, 42 h after inoculation with
fecal samples of different human subjects: healthy, UC remission
and UC relapse (n 5 4)
Healthy UC remission UC relapse
Acetate 54.0 6 3.8 40.7 6 4.9 46.1 6 6.0
Propionate 7.3 6 0.3 6.2 6 3.2 9.4 6 1.4
Butyrate 23.6 6 5.3 18.9 6 4.2 23.8 6 3.4
Valerate 0.6 6 0.6 1.6 6 0.8 0.7 6 0.6
Caproate 1.5 6 1.5 3.6 6 2.8 0.1 6 0.1
Branched SCFA 2.0 6 1.6 5.1 6 1.2 3.2 6 1.3
Total SCFA 89.1 6 2.5 76.2 6 4.6 83.3 6 7.6
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Figure 1 | Dice cluster analysis of universal DGGE gel profiles from in vitro luminal and mucosal communities of the M-SHIME colonized with
samples derived from healthy subjects,or from UC patients in remission or relapse. The luminal samples are indicated by stars (*) and the mucosal
samples are indicated by full circle (N). The dendrogram can be divided into three clusters: Cluster I: mucosal samples (54.61% similarity). Cluster II:
luminal samples (53.89% similarity). Cluster III: luminal samples (41.15% similarity). Metric scale indicates degree of similarity in percentages.
Figure 2 | Principal Component Analysis of the quantitative PCRmeasurements illustrated by. PC1 and PC2 (29.9% and 21.3% of explained variance,
respectively). Score plot showing the M-SHIME luminal (D) and mucosal (#) communities. Sources of the communities are indicated by green for
healthy subjects, blue for UC patients in remission and red for UC patients in relapse. Loading plot indicating each of the measured bacterial taxa as
determined by quantitative Real-Time PCR. 1. B. bifidum; 2. B. adolescentis; 3. B. pseudocatenulatum; 4. Bifidobacterium spp.; 5. Lactobacillus spp.; 6. C.
leptum subgroup; 7.C. coccoides group; 8. F. prausnitzii; 9.Desulfovibrio spp.; 10.Akk. muciniphila; 11. Firmicutes; 12. Bacteroidetes; 13. Roseburia spp.; 14.
Bacteroides spp.; 15. Alistipes spp.; 16. Actinobacteria; 17. Bac. fragilis group; 18. Clostridiaceae/Eubacterium.
www.nature.com/scientificreports
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intestinal microbial ecosystems of healthy subjects and UC patients,
either in relapse or in remission. This model allows investigation of
differences within the luminal content as well as at the artificial
intestinal mucosal surface23,24. The impact of the human host on
the microbial composition is eliminated, thus allowing focus on
intrinsic features of the gut microbial populations. However, as
any model, the M-SHIME has its limitations, and it should be noted
that the bacterial communities colonizing an in vitro fermentor can
never be made completely identical to those present in humans due
to e.g. possible loss of species during freezing, and altered availability
of nutrients leading to changes in the competitive advantages of other
species.
Still, in line with recent in vivo25,26 and in vitro studies27,28, we have
demonstrated that also in the M-SHIMEmodel, the in vitro mucosal
Table 2 | Preference of bacterial taxa to colonize the mucosal compartment, expressed as ratio of the relative quantities in mucosal and
luminal compartments of the M-SHIME
Ratios mucus/lumen (%)a
Bacterial taxa Health subjects UC remission UC relapse
Firmicutes 100.36 (61.23) 100.46 (61.64) 99.85 (60.89)
N Clostridiaceaecb/Eubacterium 103.18 (629.64) 117.47 (619.49) 79.53 (67.99)
N Clostridium leptum subgroup 96.33 (68.43) 83.81 (65.12)* 82.39 (63.35)*
+ Faecalibacterium prausnitzii 102.62 (613.35) 83.75 (64.22)* 93.91 (64.97)
N Clostridium coccoides group 88.47 (610.94) 74.10 (611.74) 66.81 (610.73)*
+ Roseburia spp. 108.01 (67.70) 137.83 (612.28)* 146.06 (641.24)
N Lactobacillus spp. 94.70 (68.85) 81.32 (62.77)** 68.59 (67.64)*
Bacteroidetes 99.98 (62.84) 106.52 (69.69) 94.36 (67.57)
N Bacteroides spp. 98.44 (62.87) 112.93 (69.33) 85.28 (65.06)
+ Bac. fragilis group 93.95 (67.55) 107.24 (614.33) 75.48 (68.88)
N Alistipes spp. 65.05 (17.58) 68.12 (611.76) 71.91 (68.47)*
Actinobacteria 76.29 (13.79) 55.39 (2.88)*** 52.01 (16.96)
N Bifidobacterium spp. 94.60 (63.12) 91.24 (61.53)** 84.63 (64.28)**
+ B. bifidum 93.99 (63.47) 106.37 (66.97) 84.48 (63.35)*
+ B. adolescentis 89.52 (64.61) 83.68 (61.37)*** 67.61 (616.58)
+ B. pseudocatenulatum 101.27 (64.68) 79.79 (63.55)** 94.60 (615.00)
Proteobacteria
N Desulfovibrio spp. 101.19 (61.75) 101.22 (64.53) 92.74 (63.89)
Verrucomicrobia
N Akkermansia muciniphila 85.48 (66.90) 73.15 (612.19) 86.18 (65.10)
aRatios (%) calculated as 100*mucosal samples/luminal samples, hence values below 100% indicates low adherence capacity to mucus, while values above 100% indicate high adherence capacity to
mucus.
bIncludes Clusters I, III, IV, XIVa, XIVb.
Asterisks (*) indicate significant differences between mucosal and luminal samples (*P,0.05 and **P,0.01). All calculated data are means 6 SEM.
Table 3 | Relative abudance of bacteria derived from UC patients compared to healthy subjects
Lumen Mucus
Bacterial taxa UC remission UC relapse UC remission UC relapse
Firmicutes 98.99 (62.34) 101.92 (60.52) 99.02 (60.96) 101.43 (60.40)
N Clostridiaceaeca/Eubacterium 111.60 (613.44) 142.63 (68.74)* 131.70 (69.89) 120.27 (613.98)
N Clostridium leptum subgroup 105.94 (69.04) 120.45 (63.06) 95.21 (610.49) 106.03 (64.53)
+ Faecalibacterium prausnitzii 120.28 (67.78) 125.79 (63.57) 103.39 (62.32) 122.12 (65.42)
N Clostridium coccoides group 97.68 (614.02) 119.86 (66.22) 69.89 (623.95) 94.02 (616.97)
+ Roseburia spp. 103.12 (67.65) 72.29 (611.66) 133.15 (619.83) 89.96 (624.74)
N Lactobacillus spp. 109.74 (63.52) 80.06 (612.88) 96.27 (64.42) 57.99 (68.93)***
Bacteroidetes 95.33 (611.68) 107.10 (64.71) 98.92 (66.41) 100.04 (64.25)
N Bacteroides spp. 93.35 (611.66) 110.06 (66.83) 104.27 (66.83) 94.82 (66.63)
+ Bac. fragilis group 94.12 (615.12) 113.49 (68.76) 103.68 (614.08) 88.68 (66.82)
N Alistipes spp. 100.97 (611.46) 111.57 (66.01) 100.60 (619.04) 118.90 (618.49)
Actinobacteria 101.99 (67.42) 100.10 (63.65) 74.06 (68.91) 68.72 (623.89)
N Bifidobacterium spp. 99.97 (63.72) 97.65 (62.65) 96.53 (64.95) 89.04 (64.22)*
+ B. bifidum 71.84 (624.63) 79.50 (611.98) 75.73 (624.27) 71.53 (611.61)
+ B. adolescentis 112.86 (64.80) 89.80 (615.22) 106.56 (65.15) 76.15 (623.01)
+ B. pseudocatenulatum 113.94 (67.96) 96.16 (622.55) 99.55 (68.11) 90.74 (618.72)
Proteobacteria
N Desulfovibrio spp. 117.09 (617.88) 120.72 (65.61) 117.92 (618.33) 111.03 (64.90)
Verrucomicrobia
N Akkermansia muciniphila 90.88 (619.54) 79.57 (617.82) 85.11 (624.57) 73.99 (614.50)
All numbers are average 6 SEM of the four samples in each UC group of either lumen or mucus. The relative abundance values (%) are normalized to healthy controls (set to 100).
aIncludes Clusters I, III, IV, XIVa, XIVb.
Asterisks (*) designate a significant difference from the healthy control group (*P , 0.05 and ***P,0.001).
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microbial community differs from the luminal one (Figure 1), with a
tendency of specific butyrate-producing bacteria (e.g. Roseburia
spp.) being abundant members of the mucosal microbiota (Table 2
and Figure 2). In samples from healthy people, the difference
between mucosal and luminal populations was more clearly seen
by DGGE than by qPCR, probably reflecting that by qPCR only
the subpopulations targeted by the selected primers are seen. The
luminal and mucosal bacteria have previously been demonstrated to
Figure 3 | Principal Component Analysis of LCMS data from the mucosal M-SHIME samples after colonization with microbiota derived from either
healthy subjects (#) or UC patients in relapse (D). Score (left) and loading (right) plots are shown. PC1 and PC2 explain 29.1% and18.6% of the
variance, respectively. Numbers from 1to 10 in the loading plot correspond to metabolite candidates enriched in the M-SHIME mucin-coveres
microcosms.. Masses of the candidates are given in Table 4.
Figure 4 | Principal Component Analysis of the LCMS data from the luminal M-SHIME samples after colonization with microbiota derived from
healthy subjects (#) or UC patients in relapse (D). Score (left) and loading (right) plots are shown. PC1 and PC2 explain 26.2% and 21.8% of the
variance, respectively. Numbers from 11–17 in the loading plot correspond tometabolite candidates that are enriched in the luminal M-SHIME samples.
Masses of the candidates are given in Table 5.
www.nature.com/scientificreports
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display different roles in the host, and it has been proposed that the
mucosal microbiota is more involved in interaction with the epithe-
lial and immune cells than the luminal microbiota, because it resides
closer to the intestinal epithelial cells29,30. Hence, an altered mucosal
microbial community may play an important role in dysregulated
immune responses.
In spite of a limited sample size, we found a number of statistically
significant differences between microbial communities derived from
healthy people, UC patients in remission, and UC patients in relapse,
respectively. For samples from UC patients a significantly lower
proportion of lactobacilli and bifidobacteria residing in the mucus-
microcosm than in the lumen was observed, while this was not the
case for healthymicrobiotas (Table 2). Notably, this was observed for
UC patients in remission as well for those in relapse, indicating that
the impaired ability of the lactic acid bacteria to adhere to mucus is
present also when UC patients are free of severe symptoms.
However, when directly comparing ‘mucosal’ populations from
M-SHIME colonized with microbiota from UC patients to those
colonized with healthy microbiotas, only patients in relapse had a
significantly lower amount of bifidobacteria and lactobacilli than
found in the ‘healthy’ samples (Table 3). This could be due to the
fact that microbiota fromUC patients in relapse in general contained
lower amounts of lactic acid bacteria than microbiota derived from
either healthy people or UC patients in remission. Species or strain
specific mucus adhesion promoting proteins have been reported in
several bifidobacteria and lactobacilli6,31–35. The expression of adhe-
sion molecules may be changed in the lactic acid producing bacteria
derived fromUCpatients, hence their inability to colonize themucus
in vitro. However, we would expect that host-induced differences in
bacterial gene expression profiles would no longer prevail after
42 hours in the gut model. Alternatively, an altered composition of
the species of lactobacilli and bifidobacteria derived from UC
patients may explain the decreased ability of these groups to adhere
to themucin-microcosms of theM-SHIME. A third explanationmay
be that within a given species, the strains of lactic acid bacteria
present in UC patients are less capable of adhesion to mucins than
their counterparts present in healthy subjects, perhaps due to minor
genetic differences in adhesion-relevant genes.
Bifidobacteria and lactobacilli are believed to play important roles
in promoting intestinal health36–43. The observed depletion of bifido-
Table 4 | Annotated metabolites, which differ between healthy subjects and UC patients in relapse (mucus)
Enriched in UC relapse
No. Metabolite candidate MPCA (Da)/RT (min) MLCMS (Da) MHMDB (Da) Error (mDa) P values
1 Monounsaturated fatty acids (C18) 281.5/6 281.248569 281.248627 0.058 P,0.05
2 Polyunsaturated fatty acids (C18) 279.5/6 279.232812 279.232971 0.159 P,0.05
3 Secondary bile acids 391.5/4 391.285401 391.285400 0.001 P,0.05
4 Salicyluric acid (drug) 194.5/2 194.046042 194.045883 0.159 P,0.001
5 Monounsaturated fatty acids (C18) 282.5/6 281.248569 281.248627 0.047 P,0.05
6 Aminosalicylic acid (drug metabolite) or 3-
Hydroxyanthranilic acid (oxidation product of
tryptophan metabolism)
152.5/1 152.035358 152.035309 0.049 P,0.01
7 Product of phenylalanine metabolism 149.5/3 149.060764 149.060806 0.042 P,0.01
Enriched in healthy subjects
No. Metabolite candidate MPCA (Da) MLCMS (Da) MHMDB (Da) Error (mDa) P values
8 Tryptophan 203.5/2 203.082491 203.082596 0.105 P,0.05
9 Phenylalanin 164.5/1 164.071619 164.071701 0.082 P,0.005
10 Hydroxyphenyllactic acid or 3-(3-hydroxyphenyl)-3-
hydroxypropanoic acid
181.5/2 181.050629 181.050629 0.531 P,0.05
Numbers from 1–10 correspond to the metabolite marked in the loading plot Figure 3. MPCA designates mass taken from PCA; RT designates retention time bucket of the PCA; MLCMS designates mass taken
from LCMS analysis of test samples; MHMDB designates mass given by Human Metabolome Data Base; ‘Error’ designates the mass difference between measured MLCMS and found MHMDB.
Table 5 | Annotated metabolites, which differ between healthy subjects and UC patients in relapse (lumen)
Enriched in UC relapse
No. Metabolite candidate MPCA (Da)/RT (min) MLCMS (Da) MHMDB (Da) Error (mDa) P values
11 Secondary bile acids 391.5/4 391.285527 391.285400 0.127 P,0.01
12 Salicyluric acid (drug) 194.5/2 194.046042 194.045993 0.110 P,0.001
13 Aminosalicylic acid (drug metabolite) or 3-
Hydroxyanthranilic acid (oxidation product of
tryptophan metabolism)
152.5/1 152.035358 152.035309 0.052 P,0.05
14 Product of phenylalanine metabolism 149.5/3 149.060764 149.060806 0.122 P,0.001
Enriched in healthy subjects
No. Metabolite candidate MPCA (Da) MLCMS (Da) MHMDB (Da) Error (mDa) P values
15 Tryptophan 203.5/2 203.082491 203.082596 0.278 P,0.001
16 Phenyllactic acid or 4-methoxyphenylacetic acid or
desaminotyrosine
165.5/3 165.055687 165.055710 0.023 P,0.05
17 Phenylglycine 150.5/2 150.056153 150.056046 0.107 P,0.001
Numbers from 11–17 correspond to the metabolite marked in the loading plot Figure 4. MPCA designates mass taken from PCA; RT designates retention time bucket of the PCA; MLCMS designates mass taken
from LCMS analysis of test samples; MHMDB designates mass given by Human Metabolome Data Base; ‘Error’ designates the mass difference between measured MLCMS and found MHMDB.
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bacteria and lactobacilli in UC patients in relapse, which is in line
with a number of previous reports44–46, is likely to have a consequence
for colonic health. It is, however, not possible from the given data to
conclude whether the impaired adhesion capacity of lactic acid bac-
teria derived fromUCpatients is part of the cause or part of the effect
of the disease. It may be that the mucus layers in the intestines of the
UC patients have selected for populations of lactic acid bacteria,
which are less optimized to adhere to the ‘healthy’ mucin of the
M-SHIME.
Also the ability of the butyrate-producing clostridial groups C.
coccoides and C. leptum to colonize the mucin-covered microcosms
of the M-SHIME was found to be lower in bacterial communities
from UC patients than in those originating from healthy subjects,
although for UC patients remission, this was only statistically sig-
nificant for the C. leptum group (Table 2). This may be linked to the
lower abundance of lactobacilli and bifidobacteria in the micro-
cosms, since these species produce acetate and/or lactate, which is
subsequently utilized by the given clostridial groups. In contrast to
the C. coccoides group and the C. leptum subgroup, the buturate-
producing Roseburia spp. in microbiotas originating from UC
patients demonstrated a high presence mucin-microcosms
(Table 2), indicating that these species, which are known to be able
to degrade complex carbohydrates47, are not dependent on the pres-
ence of lactate and acetate as seen for their clostridial relatives.
Hence, the low abundance of the clostridial groups within the
mucin-microcosms may create a free ecological niche allowing for
excessive colonization of Roseburia spp.
Metabolomic (LCMS) analysis revealed that the microbiotas from
healthy subjects and from UC patients in remission displayed very
similar metabolisms, while the metabolism of bacterial communities
from UC patients in relapse was clearly different from these two
groups (Figure 3, 4, S1, S2, S3 and S4). We found that metabolism
of bile acids, tryptophan and phenylalanine were altered in luminal
as well as mucosal samples derived from UC patients in relapse as
compared to healthy subjects (Table 4 and 5). The presence of drugs
and drug metabolites in samples from UC patients in relapse was
expected, since all four patients received mesalazine (5-aminosa-
licylic acid).
In the human body, most bile acids are actively reabsorbed from
the ileum and returned to the liver. However, a small fraction of bile
acids escape enterohepatic circulation and enter the colon where
bacteria metabolize the bile acids primarily by deconjugation and
oxidation of hydroxyl groups. Bile salt hydrolysis is carried out by
a broad spectrum of intestinal bacteria48,49. However, the specificity
of hydroxysteroid dehydrogenase (HSDH) varies depending on bac-
terial species and may either be specific for the 3-, 7-, and/or 12-
hydroxy groups of bile acids leading to different secondary bile acids.
Specific HSDHs have primarily been detected in a number of
Clostridium and Eubacterium species belonging to either cluster I,
IV (C. leptum subgroup), XIVa (C. coccoides group) or XIb49,50. As
we demonstrated significantly higher levels of Clostridiaceae/
Eubacterium in the luminal samples from UC patients in relapse
than in healthy subjects (Table 3), this could partly explain the
observed enrichment of secondary bile acids. High levels of second-
ary bile acids such as deoxycholic acids (primarily produced by spe-
cies belonging to Clostridiaceae) can be detrimental for colon
health51.
Phenylalanine was more abundant in mucosal samples from the
M-SHIME colonized with microbiota from healthy subjects, than in
those colonized with samples from UC patients (Table 4). Products
of phenylalanine that are normally metabolized by intestinal bacteria
undergo a variety of processes in the body, where theymay be detoxi-
fied by either glucuronide or sulphate conjugation in the gut mucosa
and liver, or remain unabsorbed and voided in feces52. Production of
phenolic compounds by proteolytic and peptidolytic activities of the
intestinal bacteria has previously been associated with various dis-
eases including cancer and UC52. Previous studies have shown that
species belonging to the genera Clostridium and Bacteroides have a
high capacity to ferment phenylalanine to phenolic compounds such
as phenylpropionate, phenylacetate and/or phenyllactate53,54. Here,
we observed higher levels of clostridia in samples derived from UC
patients than in samples from healthy subjects (Table 3). Hence, we
speculate that the enrichment of products of phenylalanine metabol-
ism in mucosal and luminal samples derived from UC patients in
relapse could be a result of the higher abundance of these bacterial
groups (Table 4 and 5).
Also tryptophan levels were higher in samples from theM-SHIME
colonized with microbiota from healthy subjects than when it was
colonized with microbiota from UC patients in relapse (Table 4 and
5). In line with this, previous studies have revealed that after fer-
mentation using inocula from healthy subjects, no products of tryp-
tophan metabolism could be detected in the system52,54.
Finally, we observed that unsaturated fatty acids (FA) were sig-
nificantly higher in mucus compartments colonized with bacteria
from UC patients in relapse than in those colonized with ‘healthy’
bacterial communities (Table 4). Previous metabolomic research has
revealed changes of FA in serum of UC patients55, and has suggested
that these changes could be caused by increased endogenous biosyn-
thesis of polyunsaturated fatty acids (PUFA) and by increased lipo-
lysis initiated by cytokines during the inflammatory response. Based
on the present work, we speculate that the altered levels of FA in
serum UC patients in relapse compared to healthy subjects could be
originating from the intestinal microbial metabolism.
In conclusion, our data suggest that the significantly altered intest-
inal bacterial community present in UC patients in relapse results in
a significantly altered bacterial metabolic profile. The observed bac-
terial alterations are suggested to result in increased metabolism of
phenylalanine and tryptophan in microbial communities from UC
patients in relapse. While UC patients in remission display micro-
biotas and metabolomes very similar to those of healthy subjects, the
lactic acid bacteria present in patients in remission are, similar to
those from the relapse samples, significantly impaired in their ability
to adhere to the mucus microcosms of the M-SHIME. This may be
due to a different composition or a different genetic makeup of the
lactic acid bacteria present in all UC patients, which may play a role
in the etiology of this disease. We suggest that probiotic therapy for
UC patients should not exclusively aim at increasing the amount of
lactic acid bacteria present in the gut, which has previously proved
helpful56, but also at replacing the existing lactic acid bacteria with
other strains/isolates with better capacity for mucosal adhesion.
Methods
Human volunteers and clinical characteristics of UC patients. Fecal samples were
obtained from 8 patients with UC and 4 healthy controls57. Within the UC group, 4
patients were in clinical remission and 4 patients had active disease at the time of
sampling according to clinical and endoscopical criteria58. The study was performed
in accordance with the Second Helsinki Declaration, reported to the Danish Data
Protection Agency and approved by the Regional Ethics Committee. Written
informed consent was obtained from each participant under a protocol approved by
the Danish National Committee on Biomedical Research Ethics. All four patients
with active UC were treated with mesalazine (5-aminosalicylic acid). Two patients
with inactive UC received mesalazine, one patient received olsalazine (6-
hydroxybenzoate)-salicylic acid), and one received no antiinflammatory treatment.
None of the participants had been treated with antibiotics for at least 2 months before
enrolment and there was no significant difference (P 5 0.32) in the mean age of the
participants when comparing the 3 groups.
Sample collection and processing. Stool samples were collected in airtight containers
and stored at 4uC (limited storage time was encouraged59) until delivery to the
laboratory. Feces were homogenized in glycerol to give a 25% feces/glycerol slurry.
This was performed in an anaerobic cabinet (Macs Work Station, Don Whitley,
containing 10% H2, 10% CO2, and 80% N2). The processed samples were stored at
280uC until further analysis.
Growth medium and chemicals. Unless stated otherwise, chemicals were obtained
from Sigma (Bornem, Belgium). The M-SHIME feed contained 1.0 g/l
arabinogalactan, 2.0 g/l pectin, 1.0 g/l xylan, 3.0 g/l starch, 0.4 g/l glucose, 3.0 g/l
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yeast extract, 1.0 g/l peptone, 4.0 g/l mucin, and 0.5 g/l cystein. Pancreatic juice
contained 12.5 g/l NaHCO3, 6.0 g/l bile salts (Difco, Bierbeek, Belgium) and 0.9 g/l
pancreatin. Mucin agar was prepared by boiling autoclaved distilled H2O containing
5% porcine mucin type II and 1% agar. The pHwas adjusted to 6.8 with 10 MNaOH.
M-SHIME. Analysis in the M-SHIME dynamic gut model was carried out as
previously described27 at two different occasions with six participants for each 42-
hours run (two healthy, twoUCpatients in remission and twoUCpatients in relapse).
The position (vessel) of the inocula from either healthy subjects or UC patients was
changed for each run.
Microbial activity in terms of short-chain fatty acids (SCFA). Acetate, propionate,
butyrate, valerate, caproate and branched SCFA (isobutyrate, isovalerate and
isocaproate) were measured as described previously60.
Extraction of bacterial DNA. Before extraction of the mucosal samples, the samples
were heated for 15 min at 55uC to make the agar soluble. Subsequently, DNA was
extracted from thawed samples using the QIAamp DNA Stool mini kit (Qiagen,
Hilden, Germany) with a bead beater step in advance, as previously described61. For
each sample, DNA was extracted in duplicates. The purified DNA was stored at
220uC until use.
PCR amplification for DGGE.Aliquots (10 mL) of purified DNA (5 ng/ml of pooled
DNA from the duplicate DNA extractions) were applied to the following to give a
50 mL PCR reaction mixture: 20 ,L of 5 PRIME MasterMix (2.53) (VWR & Bie &
Berntsen) and 10 pmol of each of the primers (Eurofins MWG Synthesis GmbH,
Ebersberg, Germany). Primers HDA1-GC/HDA262 targeting 16S rRNA genes from
all bacteria were used in a touchdown PCR as previously described63.
Analysis of luminal and mucosal microbiota by DGGE. DGGE was carried out as
described previously64 using a DcodeTM Universal Mutation Detection System
instrument and gradient former model 475 according to the manufacturer’s
instructions (Bio-Rad Labs, Hercules, California). The 9% polyamide gels were made
with denaturing gradients ranging from 25% to 65%. The 100% denaturant solution
contained 40% formamide and 7 M urea. Thirteen microlitres PCR products were
mixed with 3 mL loading dye before loading. Gels were run in 1 x TAE at 60 uC for
16 h at 36 V, 28 mA, stained with ethidium bromide for 15 min, destained for
20 min, and viewed by UV-B trans illumination at 302 nm (Bio-Rad). The
BioNumerics software, version 4.60 (Applied Maths, Sint-Martens-Latem, Belgium)
was used for identification of bands and normalization of band patterns from DGGE
gels. DGGE gels were normalized by an assigned marker (developed in our
laboratory). A cluster analysis was performed based on Dice coefficient of similarity
(weighted) using the unweighted pair group method and the arithmetic averages
clustering algorithm.
Quantitative PCR assay conditions. QPCR was performed on an ABI Prism
7900 HT from Applied Biosystems. The amplification reactions were carried out in a
total volume of 11 mL containing; 5.50 mL (SYBRH Green, Applied Biosystems),
primers (each at 200 nM concentration) (Eurofins MWG Synthesis GmbH), 2 mL
templateDNA, andNuclease-free water (Qiagen) purified for PCR. The amplification
was carried out as previously described65. DNA (5 ng/ml) from the duplicate DNA
extractions of each sample was used for the qPCR.
Quantitative PCR primer and data handling. The primers specific to regions of the
16S rRNA genes of 20 selected bacterial taxa are listed in Table S1 (supplementary
data). The taxawere selected based on an expected relevance to human health, and the
specificity of the primers under the given conditions has recently been verified66. The
relative quantities of gene targets encoding gene sequences of the bacterial taxa were
calculated using 2DeltaCt, assuming primer efficiency at 1.0. Delta Ct is the Ct-values of
the bacterial target normalized against Ct-values of the total bacterial population in a
sample. Ct is the threshold cycle calculated by the ABI software (SDS version 2.2;
Applied Biosystems, Foster City, California, USA) as the PCR cycle, where
amplification signal exceeds the selected threshold value, also set by the ABI software.
Prior to the quantification, standard curves were created using serial 10-fold dilutions
of bacterial DNA extracted from one of the M-SHIME samples for all primer sets.
Analysis of the standard curves allowed verification of PCR efficiency for the chosen
PCR conditions. All primers were tested to confirm sensitivity and specificity using
DNA from pure bacterial species (Table S2, supplementary data). The detection limit
was set to 0.001% of the quantity of the total bacteria. Bacterial targets that could not
be detected or were below the detection limit were set to one half of the detection limit
for further calculations.
Metabolite detection & identification. Luminal samples from the M-SHIME were
thawed on ice and subsequently centrifuged at 3000 g for 15 min at 4uC. Cold
methanol (around 280uC) in a ratio 151 was added to the supernatant. Metabolites
from the mucosal samples, due to the semi-solid form, were extracted with 2 ml of
cold 50% methanol and centrifuged at 3000 g for 15 min at 4uC. This procedure was
repeated twice. All of the samples were stored at 280uC until further analysis and
centrifuged at 15000 g for 5 min at 4uC just before LCMS analysis. The analysis of
metabolites was conducted as follow: a Dionex Ultimate 3000 RS liquid
chromatigraph (Dionex, Germering, Germany) coupled to a Bruker maXis time of
flightmass spectrometer equippedwith an electrospray interphase (BrukerDaltonics,
Bremen, Germany). Analytes were separated on Kinetex pentafluorophenyl column
50 x 2.10 mm, 2.6 mm, 100 A˚ (Phenomenex, USA), using the solvent system: A,
10 mM ammonium formate pH 3.5, and B, acetonitrile. Solvent programming was
isocratic 0% B to 0 min followed by a linear gradient to 100% B at 7 min and 100% B
at 8 min. Flow rate was 0.25 ml/min at 0 min, increased to 0.4 ml/min at 7 min.
Solvent composition and flowwere returned to initial conditions at 8.2 min. The oven
temperature was 40uC. Injection volumes were 1 ml. The following electrospray
interphase settings were used: nebulizer pressure 2 bar, drying gas 10 l/min, 200uC,
capillary voltage 4000 V. Scan range was from 50 to 800 m/z. The main focus of this
study was acids, thus samples were analyzed in negative mode.
To identify metabolites seen to separate given groups, the Human Metabolome
Database (HMDB; Wishart et al. 2009) was used. Molecular formulas of the meta-
bolites from the LCMS analysis were generated based on exact mass and isotopic
pattern with Bruker Daltonics Software. Identification of metabolites was based on a
very low measurement error (Tab.1, Tab.2; external & internal calibration and lock
mass was used), compared to the data given in HMDB and further references to the
microbial metabolism in the GI. In addition hydrophobic properties of the molecule,
indicated by the retention time in the chromatograph, were taken into consideration.
Statistical analysis. Statistical analysis of the qPCR data was performed using
OriginPro software (version 8.1; OriginLab Corporation, Northampton, USA).
Normality and homogeneity of variances of the qPCR data were assessed using the
Kolmogorov-Smirnov and the Levene’s test, respectively. Log-transformations were
performed for data that did not meet these criteria. T-testing was apllied to identify
significant differences in colonization ability using the ratio (proportion) of the given
bacterial taxon present in the two communities (lumen and mucus) for the three
groups (healthy, UC patients in remission and UC patients in relapse). Univariate
ANOVAwas used to determine significant differences between specific bacterial taxa
comparing the three groups either from lumen ormucus.Where ANOVA indicated a
significant difference, Fisher’s least significant different test was used. The
nonparametric Kruskal-Wallis test was used for datasets, which did not have
homogeneity of variance or were not normally distributed even after log-
transformation. Univariate ANOVA was applied to confirm that there was no age
differences between the three disease groups. Tests were considered statistically
significant if P-values lower than 0.05 were obtained. Principal Component Analysis
(PCA) of qPCR data was carried out using LatentiXH data analytical software (version
2.00, TheMathworks Inc., Copenhagen, Denmark). Differences inmetabolite profiles
were evaluated by PCA using Profile Analysis 2.0 by Bruker Daltonics. Data was
grouped into buckets of 1 min and 1 m/z differences in the range from 0.5 to 9 min
and 50 to 800 m/z and normalized by the sum of buckets in the analysis. P-values
were calculated by univariate ANOVA (a 5 0.05) using the normalized values from
the PCA. As for the qPCR analysis, tests were considered significant when P-values
lower that 0.05 were obtained.
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